dfwl28, thanks for sharing the article !!! So ... What

New Post Public Reply Private Reply Replies (1) Message Board
TechGuru
840
dfwl28, thanks for sharing the article !!!

So ... What are waiting for ??? Let the trials begin !!!

Quote:
Discussion:
In the present study, we investigated the expression of CCR5 in samples from UC. We compared the expression levels in those samples to levels from tissue samples of other common tumors known to express high levels of CCR5 using an inhibitor-based IHC assay. To our knowledge, this is the first report of high levels of expression of CCR5 protein in UC in comparison to other tumors. With the maturation of CCR5 as a therapeutic target, our results may have clinical applications in treating this disease. The CCR5 is a G protein-coupled receptor belonging to the beta chemokine receptors family of integral membrane proteins predominantly seen on T cells, macrophages, dendritic cells, eosinophils, microglia, and a subpopulation of breast or prostate cancer cells10. Recent studies indicate that CCR5 inhibitors blocked the migration and metastasis of breast and prostate cancer cells that expressed CCR511,12. Sicoli et al. examined the molecular mechanisms governing prostate cancer bone metastasis by tranducing FVB murine prostate epithelium with oncogenic v-Src. These prostate cancer cell lines metastasized in FVB mice to brain and bone. Sicoli et al’s - gene expression profiling of the tumors identified activation of a CCR5 signaling module when the prostate epithelial cells lines were grown in vivo vs. tissue cultures. The authors were then able to reduce the whole body, bone and brain metastatic prostate cancer burden by oral CCR5 antagonist. Other studies suggested that CCR5 is expressed in some cancer stem cells, which are known to drive therapy resistance, and that CCR5 inhibitors may enhance the cancer response to chemotherapy. There is very little literature investigating the association between UC and CCR5 variations. A few authors examined the effects of polymorphism in the genes encoding for CCR5 and the risk of UC in different populations. Kucukgergin et al. genotyped 142 histologically confirmed BC patients and 197 controls and demonstrated a positive association between CCR5Δ32 gene polymorphisms and BC risk. The frequency of the heterozygous wt/Δ32 genotype of CCR5 was more prevalent in BC patients than in controls14. Also, previously, genetic variants in CCR5 (CCR5wt/Δ32 andCCR5Δ32 alleles) were reported to confer a significantly high risk for early-onset smoking-related tumors. Srivastava et al. examined CCR5 Δ32 polymorphism in conferring genetic susceptibility to GBC. They found that such polymorphism was associated with gallbladder cancer, particularly in patients with early-onset and tobacco usage15. This a finding which bears significance since smoking is the number one risk factor for the development of BC. Our results, if validated, may have therapeutic implications. CCR5 inhibitors have been shown to block metastasis of breast and prostate cancer. Velasco-Velázquez et al. conducted microarray analysis on 2,254 human breast cancer specimens and found increased expression of CCR5 in the basal and HER-2 genetic subtypes. The authors then showed that the CCR5 antagonists maraviroc or vicriviroc, developed to block CCR5 HIV coreceptor function, reduced in vitro invasion of basal breast cancer cells, and maraviroc decreased pulmonary metastasis in a preclinical mouse model of breast cancer. Velasco-Velázquez et al. then concluded that CCR5 antagonists might be used as an adjuvant therapy to reduce the risk of metastasis in patients with the basal breast cancer subtype11. The current study used an assay based on a diagnostic version of PRO140, a CCR5 humanized monoclonal antibody against CCR5 that, in pharmacologic form (leronlimab), showed proven efficacy and safety profile. A sub-Q injection form of PRO 140 was tested as monotherapy in HIV-1. It was generally well tolerated relative to placebo and demonstrated potent and prolonged CCR5 blocking activity when administered weekly or every other week16. Therefore, CCR5 inhibitors such as Leronlimab, Maraviroc, and Bristol Myers Squibb BMS-813160 may be potential therapeutic options for patients with UC. Patients may also benefit from a combination of CCR5 inhibitors with currently approved systemic treatment for UC. Functional CCR5 was highly expressed by tumor infiltrating Treg, and CCR5 high Treg was previously shown to be more suppressive than their CCR5 low Treg counterparts17. Therefore, blockade of CCR5 on regulatory T cells (Treg) in combination with PD-L1 blockade could reduce the Treg suppression of CD8 cells and allow the anti-tumor activity of CD8 cells to endure in patients with BC treated with PD-L1 inhibitors such as pembrolizumab and Nivolumab. Also, since CCR5 is expressed on stem-like cancer cells, CCR5 inhibitors may potentiate the response to chemotherapy in the basal type of BC that is generally unresponsive to immunotherapy and thus resembles the basal type of breast cancer


It would seem that "our" BP still has access to some Leronlimab, he is co-author of the article.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading